Increasing the Utility of Real-World Data to Inform Public Health Decision Making Through a US-based Private-Public Partnership: 10 Lessons Learned from a Principled Approach to Rapid Pandemic RWE Generation
- PMID: 40102361
- PMCID: PMC12018611
- DOI: 10.1007/s43441-025-00748-4
Increasing the Utility of Real-World Data to Inform Public Health Decision Making Through a US-based Private-Public Partnership: 10 Lessons Learned from a Principled Approach to Rapid Pandemic RWE Generation
Abstract
In response to the COVID-19 pandemic, a collaborative public-private partnership was launched to harness evidence from rapidly accruing real-world data (RWD) in various healthcare settings, with the goal of characterizing and understanding COVID-19 in near real-time, by applying rigorous epidemiological methods and defining research best practices. Projects were conducted in 4 phases: Research Planning and Prioritization, Protocol Development, Protocol Implementation, and Results Dissemination. During these projects, areas were identified with a current or future need to enhance existing best practices. This report provides a summary of our research processes, including application of new and existing practices, along with key learnings related to the challenges of conducting research when the clinical landscape is rapidly evolving as was the case during the first year of the COVID-19 pandemic. Such processes and learnings may be helpful to the broader research community when using RWD to understand or address future public health priorities.
Keywords: COVID-19; Epidemiologic methods; Pandemic preparedness; Real-world data; Real-world evidence; SARS-CoV-2.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Conflict of interest: This paper reflects the views of the authors and should not be construed to represent FDA views or policies. Dr. Gatto, Dr. Garry and Ms. Wang are employees of Aetion, Inc., with stock options. During the design, analysis, and interpretation of the research project, Ms. Roe and Ms. Zariffa were affiliated with the U.S. Food and Drug Administration. All other authors declared no competing interests for this work.
Figures
References
-
- Bramante CT, Johnson SG, Garcia V, Evans MD, Harper J, Wilkins KJ, Huling JD, Mehta H, Alexander C, Tronieri J, Hong S, Kahkoska A, Alamgir J, Koraishy F, Hartman K, Yang K, Abrahamsen T, Stürmer T, Buse JB. Diabetes medications and associations with Covid-19 outcomes in the N3C database: a national retrospective cohort study. PLoS ONE. 2022;17(11):e0271574. 10.1371/journal.pone.0271574. - PMC - PubMed
-
- Brannock MD, Chew RF, Preiss AJ, Hadley EC, McMurry JA, Leese PJ, Girvin AT, Crosskey M, Zhou AG, Moffitt RA, Funk MJ, Pfaff ER, Haendel MA, Chute CG, N3C and RECOVER Consortia. Long COVID risk and Pre-COVID vaccination: an EHR-based cohort study from the RECOVER program. Medrxiv. 2022;10(06):22280795. 10.1101/2022.10.06.22280795.
-
- Wong R, Vaddavalli R, Hall MA, Patel MV, Bramante CT, Casarighi E, Johnson SG, Lingam V, Miller JD, Reusch J, Saltz M, Stürmer T, Tronieri JS, Wilkins KJ, Buse JB, Saltz J, Huling JD, Moffitt R. N3C consortium: effect of SARS-CoV-2 infection and infection severity on longer-term glycemic control and weight in people with type 2 diabetes. Diabetes Care. 2022;45(11):2709–17. 10.2337/dc22-0730. - PMC - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous